1. Home
  2. DSP vs SABS Comparison

DSP vs SABS Comparison

Compare DSP & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$10.52

Market Cap

213.3M

Sector

Technology

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.73

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSP
SABS
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
213.3M
201.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DSP
SABS
Price
$10.52
$3.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$17.75
$10.75
AVG Volume (30 Days)
221.7K
741.7K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
157.14
N/A
EPS
0.36
N/A
Revenue
$344,201,000.00
N/A
Revenue This Year
$20.27
N/A
Revenue Next Year
$16.88
N/A
P/E Ratio
$29.28
N/A
Revenue Growth
19.00
N/A
52 Week Low
$8.11
$1.20
52 Week High
$16.25
$6.60

Technical Indicators

Market Signals
Indicator
DSP
SABS
Relative Strength Index (RSI) 40.61 41.66
Support Level $8.34 $3.43
Resistance Level $10.73 $4.19
Average True Range (ATR) 0.49 0.14
MACD -0.11 -0.01
Stochastic Oscillator 6.27 3.23

Price Performance

Historical Comparison
DSP
SABS

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: